Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • Orexigen

    - PMLiVE

    Reframing the Obesity Conversation: Key Takeaways from ObesityWeek® 2025

    As the understanding of obesity continues to evolve, so too does the science, patient experience, and cross-sector collaboration driving innovation. At ObesityWeek® 2025 in Atlanta, experts from across Inizio reflected...

    Inizio

    - PMLiVE

    Eli Lilly’s oral weight-loss candidate orforglipron shows promise in late-stage trial

    The company is planning to submit the candidate for regulatory review by the end of the year

    - PMLiVE

    Novo Nordisk and Septerna enter $2.2bn cardiometabolic disease partnership

    The companies will launch four development programmes for potential small molecule therapies

    - PMLiVE

    Novo shares phase 3 results for obesity candidate CagriSema in diabetes patients

    The company is expecting to file for the first regulatory approval of the drug next year

    - PMLiVE

    Roche and Zealand partner on mid-stage obesity candidate in deal worth $5.3bn

    The companies will develop petrelintide as both a standalone therapy and in combination with Roche’s CT-388

    - PMLiVE

    Novo shares promising results for high-dose semaglutide in late-stage obesity study

    The experimental dose is also being evaluated in adults with obesity and type 2 diabetes

    - PMLiVE

    Novo Nordisk and Valo Health expand alliance for cardiometabolic diseases

    The partners are aiming to develop new drugs for type 2 diabetes, obesity and cardiovascular disease

    - PMLiVE

    Eli Lilly announces $3bn expansion to US injectables manufacturing facility

    The investment will help Lilly meeting the growing demand for its diabetes and obesity medicines

    - PMLiVE

    Amgen’s investigational weight-loss drug MariTide shows promise in mid-stage study

    The company has announced a phase 3 programme across obesity and related conditions

    - PMLiVE

    Eli Lilly and HAYA Therapeutics enter metabolic condition partnership worth $1bn

    The companies will aim to discover regulatory genome targets for obesity and related metabolic conditions

    - PMLiVE

    Eli Lilly’s GIP/GLP-1 receptor agonist tirzepatide shown to significantly reduce type 2 diabetes risk

    More than 5.6 million people in the UK are estimated to be living with a form of diabetes

    - PMLiVE

    Eli Lilly’s GIP/GLP-1 receptor agonist tirzepatide shows promise in phase 3 heart failure study

    Almost 60% of those affected by HFpEF in the US are also living with obesity

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links